Creo Medical Group PLC Speedboat RS2 advances beyond initial pilot centre
November 29 2017 - 1:01AM
RNS Non-Regulatory
TIDMCREO
Creo Medical Group PLC
29 November 2017
Creo Medical Group plc
("Creo" or "the Company")
Speedboat RS2 advances beyond initial pilot centre
Speedboat RS2 utilised at second NHS site
Chepstow, South Wales - 29 November 2017 - Creo Medical Group
plc (AIM: CREO) is pleased to announce that Speedboat RS2 has been
used by a second Gastroenterologist at a second NHS site to treat
further patients. This follows the announcement earlier this year
with the first patient being treated at St Marks hospital in
London.
Initial feedback from the first two cases at this site confirmed
the removal of lesions under local anaesthetic with a procedure
time of under one hour. The patients were discharged on the same
day and are now under routine follow-up and monitoring. We await
final histology results.
Craig Gulliford, Chief Executive Officer of Creo Medical,
commented: "We are excited by today's announcement as it provides
further validation of our technology. It is incredible that these
patients were conscious, talking to the endoscopist and able to
watch the procedure live on screen. While we need to collect
additional supportive clinical data, we are encouraged by the
results we've seen to date. We believe that procedures like this
have the potential to eliminate the need for subsequent bowel
surgery, with the obvious patient benefits aligned with material
advantages to the healthcare system in terms of cost and patient
safety."
Contacts
Creo Medical: Cenkos: FTI Consulting:
Richard Rees Camilla Hume / Mark Brett Pollard
+44 (0)1291 606005 Connelly (NOMAD) / Mo Noonan
richard.rees@creomedical.com Michael Johnson / +44 (0)203 727
Russell Kerr (Sales) 1000
+44 (0)207 397 8900 creo@fticonsulting.com
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on improving patient outcomes by applying microwave and
radiowave energy to a range of minimally invasive surgical devices.
Creo has developed CROMA, an electrosurgical platform that combines
bipolar radiofrequency, for precise localised cutting, and
microwaves, for controlled coagulation. This technology provides
physicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy; an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing safer, less-invasive and more cost-efficient
option of treatment.
For more information about Creo Medical please see our website,
www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGGMUGUPMUUB
(END) Dow Jones Newswires
November 29, 2017 02:01 ET (07:01 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024